AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19536165
Drug: Daily replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily replacement of one meal with a low-calorie diet formula
Trial: 17352632
Drug: 904-nm low-level
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 904-nm low-level laser irradiation (10 mW/cm² power density, 4 mW output power, 0.4 cm² spot size, 0.48 J dose per session, 120-sec treatment time)
Trial: 17352632
Drug: Placebo-laser therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-laser therapy
Trial: 11444788
Drug: Misoprostol 35-microg
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol 35-microg suppositories
Trial: 11444788
Drug: Misoprostol 50-microg
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol 50-microg suppositories
Trial: 22588152
Drug: Adjuvant platinum-based
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant platinum-based chemotherapy in T2a patients with KRAS wild-type tumors
Trial: 22588152
Drug: Adjuvant platinum-based
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant platinum-based chemotherapy in T2a patients with KRAS mutant tumors
Trial: 22588152
Drug: Adjuvant platinum-based
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant platinum-based chemotherapy in T2b to T3 patients with KRAS wild-type tumors
Trial: 22588152
Drug: Adjuvant platinum-based
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant platinum-based chemotherapy in T2b to T3 patients with KRAS mutant tumors
Trial: 17873571
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of antipyretics
Trial: 17873571
Drug: Alteration in
RxNorm normalized name: SLICK ALTERATION DISRUPTING BOS TAURUS G.(NC_037347.1) FS(39099129-39099368) IN EXON 9 OF PRLR GENE IN BOS TAURUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alteration in antimicrobial therapy
Trial: 15955899
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg temsirolimus
Trial: 15955899
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg temsirolimus
Trial: 12922087
Drug: DTPa-HBV-IPV/Hib vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPa-HBV-IPV/Hib vaccine administered in one injection
Trial: 12922087
Drug: DTPa-IPV/Hib and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPa-IPV/Hib and HBV vaccines administered in two simultaneous injections
Trial: 1499875
Drug: Gabexate mesylate
RxNorm normalized name: mesylate
DrugBank: Gabexate (DB12831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabexate mesylate (FOY) 12 mg/kg/day as continuous intravenous infusion for a minimum of 4 days and a maximum of 12 days
Trial: 6580858
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone 20 mg/kg/day for three consecutive days
Trial: 6580858
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone regime
Trial: 3534764
Drug: Amoxicillin-clavulanic acid
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanic acid (single drug therapy)
Trial: 3534764
Drug: Ampicillin-gentamicin-metronidazole (triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin-gentamicin-metronidazole (triple combination)
Trial: 29786702
Drug: 6% hydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% hydrogen peroxide (H2O2) gel
Trial: 29786702
Drug: 37.5% hydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 37.5% hydrogen peroxide (H2O2) gel
Trial: 23092714
Drug: rAd-Erns-E2 (2×10(6)
RxNorm normalized name: RAD-IFN
DrugBank: Nadofaragene firadenovec (DB17381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rAd-Erns-E2 (2×10(6) TCID(50) administered intramuscularly two times with a 21-day interval)
Trial: 9112320
Drug: Nonoperative care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative care (including medications, exercise, injection therapy, and manipulation)
Trial: 9112320
Drug: Inflammation's effect
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inflammation's effect on treatment effectiveness
Trial: 1426660
Drug: Ribosomal vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribosomal vaccine (D53)
Trial: 3872688
Drug: Fendosal with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fendosal with food (200 mg)
Trial: 3872688
Drug: Fendosal with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fendosal with antacid (200 mg)
Trial: 29943508
Drug: Epidural analgesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural analgesia with adrenaline 2 μg/mL
Trial: 24592958
Drug: End-of-life care
RxNorm normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: End-of-life care communication provided by physicians-in-training (internal medicine residents and medical subspecialty fellows)
Trial: 15983674
Drug: Conventional insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional insulin (CI) therapy
Trial: 2571595
Drug: Norgestimate (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norgestimate (0.25 mg) combined with 0.035 mg ethinyl estradiol (NGM 0.25/35)
Trial: 2571595
Drug: Lo/Ovral (0.30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lo/Ovral (0.30 mg norgestrel combined with 0.030 mg ethinyl estradiol)
Trial: 31088392
Drug: Ciclosporin Pro
RxNorm normalized name: Climara Pro
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciclosporin Pro (gel-based emulsion)
Trial: 22666385
Drug: Peer Review
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer Review (PR) treatment
Trial: 22666385
Drug: Non-Peer Review
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-Peer Review (non-PR) treatment
Trial: 17503661
Drug: Transient combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transient combination antiretroviral treatment (CART)
Trial: 15469659
Drug: Almond supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almond supplementation (52 g/d) for 6 months
Trial: 10091160
Drug: Glibenclamide administration
RxNorm normalized name: glibenclamide
DrugBank: Glyburide (DB01016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glibenclamide administration
Trial: 7818923
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of antithyroid antibodies (ATA) in gastric cancer patients
Trial: 7818923
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of antithyroid antibodies (ATA) in healthy controls
Trial: 7818923
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of antithyroid antibodies (ATA) in patients with other malignant tumours (OMT)
Trial: 3259104
Drug: No sedative
RxNorm normalized name: MedActive Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No sedative or analgesic drugs (Control)
Trial: 26604214
Drug: Intravenous iloprost
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous iloprost (2.0 ng/kg/min) continuous infusion for 72 hours postoperatively
Trial: 22913908
Drug: nano‐formulated indomethacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nano‐formulated indomethacin 20 mg (fasted)
Trial: 22913908
Drug: nano‐formulated indomethacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nano‐formulated indomethacin 40 mg (fasted)
Trial: 22913908
Drug: indomethacin 50
RxNorm normalized name: indomethacin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: indomethacin 50 mg (fasted)
Trial: 22913908
Drug: nano‐formulated indomethacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nano‐formulated indomethacin 40 mg (fed)
Trial: 22913908
Drug: indomethacin 50
RxNorm normalized name: indomethacin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: indomethacin 50 mg (fed)
Trial: 22913908
Drug: nano‐formulated indomethacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nano‐formulated indomethacin 40 mg and indomethacin 50 mg
Trial: 15788469
Drug: Darbepoetin‐alpha (DA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darbepoetin‐alpha (DA) administered subcutaneously weekly
Trial: 15788469
Drug: Epoetin‐beta (EB)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin‐beta (EB) administered subcutaneously weekly
Trial: 8765425
Drug: rhIL-3 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIL-3 at 5 or 10 micrograms/kg per day on days 4-13 after chemotherapy
Trial: 2109926
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 40 clot‐lysis megaunits (cIMU) double‐chain rt‐PA over 1.5 hours followed by 20 cIMU over 5 hours (infusion group, n = 12)
Trial: 2109926
Drug: 4 intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 intravenous bolus injections of 10 cIMU at 20 minute intervals (bolus group, n = 14)
Trial: 31013275
Drug: LEAN program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEAN program (Lay health supporters, E-platform, Award, and iNtegration) with mobile text messaging for medication reminders and health education
Trial: 31013275
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving community-based free-medicine program
Trial: 23594362
Drug: Intravenous vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vitamin C at 320 mg/kg body weight
Trial: 23594362
Drug: Intravenous vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vitamin C at 480 mg/kg body weight
Trial: 17630550
Drug: Interferon-based therapy
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-based therapy (peginterferon alfa-2a plus ribavirin)
Trial: 17630550
Drug: Baseline HCV-RNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline HCV-RNA levels (<= 400,000 IU/ml vs > 400,000 IU/ml)
Trial: 17630550
Drug: HIV treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV treatment (with a protease inhibitor or non-nucleoside reverse transcriptase inhibitor)
Trial: 11264734
Drug: Interferon‐α (IFN)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon‐α (IFN) therapy
Trial: 9874048
Drug: Intravenous nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nitroglycerin infusion (23 patients)
Trial: 7954556
Drug: Ramipril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (5 mg)
Trial: 28729361
Drug: Anacetrapib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anacetrapib (100 mg/d)
Trial: 28729361
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg/d plus placebo
Trial: 28729361
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus Anacetrapib (100 mg/d)
Trial: 16626581
Drug: Group 2
RxNorm normalized name: Chlamydophila psittaci biogroup 2 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 (7.8-11.0 mmol/L)
Trial: 16626581
Drug: Group 3
RxNorm normalized name: Chlamydophila psittaci biogroup 3 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 3 (≥ 11.0 mmol/L)
Trial: 9156371
Drug: 600-mg zileuton
RxNorm normalized name: zileuton 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600-mg zileuton at 7 AM
Trial: 9156371
Drug: 600-mg zileuton
RxNorm normalized name: zileuton 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600-mg zileuton at 11 PM
Trial: 9156371
Drug: 600-mg zileuton
RxNorm normalized name: zileuton 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600-mg zileuton four times daily for 5 days
Trial: 23875741
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with tiotropium and formoterol
Trial: 14738659
Drug: Screening group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening group (group A) with six monthly alpha-fetoprotein (AFP) assays
Trial: 9062523
Drug: Sucrose tablet
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose tablet (3 g)
Trial: 9062523
Drug: Aspartame-polydextrose tablet
RxNorm normalized name: Polydextrose
DrugBank: Polydextrose (DB14836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspartame-polydextrose tablet (3 g)
Trial: 9062523
Drug: Unsweetened polydextrose
RxNorm normalized name: Polydextrose
DrugBank: Polydextrose (DB14836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unsweetened polydextrose tablet (3 g)
Trial: 3320950
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy (CNS prophylaxis and reinductions every 6 weeks for 36 months)
Trial: 29940669
Drug: DHEA (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA (100 mg/day for 28 days)
Trial: 26655558
Drug: cisplatin 100
RxNorm normalized name: CISPLATIN 100MG/VIL (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cisplatin 100 mg/m(2) with conventional radiotherapy (cis100 + RT)
Trial: 26655558
Drug: cisplatin 40
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cisplatin 40 mg/m(2) weekly with accelerated radiotherapy (cis40 + ART)
Trial: 24338186
Drug: Maixuekang Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maixuekang Capsule (MKC) combined with routine medication
Trial: 24338186
Drug: Routine medication
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine medication (Control)
Trial: 21471106
Drug: MP-376 120
RxNorm normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MP-376 120 mg every day
Trial: 21471106
Drug: MP-376 240
RxNorm normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MP-376 240 mg every day
Trial: 21471106
Drug: MP-376 240
RxNorm normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MP-376 240 mg twice a day
Trial: 21471106
Drug: MP-376 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MP-376 (all doses)
Trial: 18266872
Drug: Initially non‐submerged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initially non‐submerged implants (group A)
Trial: 18266872
Drug: Initially submerged
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initially submerged implants (group B)
Trial: 17192453
Drug: Evidence-based medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based medicine (EBM) curriculum; n=38
Trial: 17192453
Drug: Non-evidence-based medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-evidence-based medicine (non-EBM); n=39
Trial: 12653261
Drug: Vitamin B12
RxNorm normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B12 tablets at a dose of 2 mg 3 times a week for 6 weeks
Trial: 11012489
Drug: Closed-loop administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop administration of propofol/alfentanil
Trial: 11012489
Drug: Closed-loop administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop administration of isoflurane/nitrous oxide
Trial: 8826539
Drug: Intranasal cocaine
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal cocaine hydrochloride (0.9 mg/kg)
Trial: 31446884
Drug: Baseline plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline plasma zinc ≥106.9 μg/dL
Trial: 31446884
Drug: Baseline plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline plasma zinc <106.9 μg/dL
Trial: 31446884
Drug: Baseline plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline plasma zinc <103.3 μg/dL
Trial: 31446884
Drug: Baseline plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline plasma zinc ≥103.3 μg/dL
Trial: 20445015
Drug: Phenelzine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenelzine (15 mg, 3 times daily; positive control)
Trial: 20445015
Drug: Selegiline (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline (5 mg, twice daily)
Trial: 20445015
Drug: Rasagiline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rasagiline (1 mg/d for 14 days)
Trial: 20445015
Drug: Rasagiline (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rasagiline (2 mg/d for 14 days)
Trial: 20445015
Drug: Rasagiline (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rasagiline (2 mg/d for 30 days)
Trial: 20445015
Drug: Rasagiline (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rasagiline (4 mg/d)
Trial: 20445015
Drug: Rasagiline (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rasagiline (6 mg/d)
Trial: 16185377
Drug: Ongoing treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ongoing treatment for depression
Trial: 16185377
Drug: Living in
RxNorm normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Living in institutions and number of medications
Trial: 12354212
Drug: C. albicans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C. albicans positive post-treatment
Trial: 12354212
Drug: Reduction in
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction in prevalence from baseline to post-treatment
Trial: 2158410
Drug: Guar gum
RxNorm normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guar gum (5 g three times daily)
Trial: 7341065
Drug: Tobramycin Ointment
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin Ointment
Trial: 28642210
Drug: Aspirin 100mg
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 100mg for 1 year
Trial: 28642210
Drug: Aspirin 100mg
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 100mg + PPI for 1 year
Trial: 25990828
Drug: High molecular
RxNorm normalized name: dextran, high molecular weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High molecular weight sodium hyaluronate (SH) at a dosage of 9 mg three times a day for 30 days
Trial: 23683447
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 40mL of 0.25% lidocaine with 0.05mg fentanyl and 0.5mg vecuronium (n=30)
Trial: 21159683
Drug: 400 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 μg misoprostol administered 3 hours prior to IUD insertion
Trial: 21159683
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered 3 hours prior to IUD insertion
Trial: 19002702
Drug: Bupropion (BUP)
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion (BUP) 300 mg for 7 days after 150 mg for 3 days
Trial: 17701883
Drug: Propylthiouracil (6-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propylthiouracil (6-8 mg/kg/day)
Trial: 15651715
Drug: Propofol (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (8 mg/kg for the first 30 min, followed by 6 mg/kg for maintenance in a 50% O2/N2O mixture)
Trial: 10063490
Drug: mecamylamine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mecamylamine (2.5 mg tablet)
Trial: 2180995
Drug: 2% and
RxNorm normalized name: clindamycin phosphate 12 mg in 1 g / tretinoin 0.25 mg in 1 g TOPICAL GEL [Clindamycin Phosphate 1.2% and Tretinoin 0.025%]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% and 3% topical minoxidil
Trial: 759879
Drug: Penicillamine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penicillamine (600 to 900 mg)
Trial: 30891960
Drug: community treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: community treatment as usual (TAU)